Revenue segments as reported by the company.

Instruments & Accessories

Systems

Services

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Intuitive Surgical

Intuitive Surgical, Inc. engages in the development, manufacture, and marketing of da Vinci Surgical Systems, and related instruments and accessories for invasive surgery. Its products include Da Vinci and Ion. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Intuitive Surgical reports robust Q4 performance and eyes future growth

Intuitive Surgical's Q4 2022 showcased strong performance and growth in procedures and system placements.
While facing challenges like macroeconomic uncertainty and supply chain costs, the company is poised for continued innovation.
Opportunities lie in expanding markets, advancing technology, and improving surgical outcomes through collaboration.
Investments in industrial scale, automation, and platform advancements signal a strategic focus on future growth.

Intuitive Surgical (ISRG) reports robust Q1 performance and growth outlook

Intuitive Surgical (ISRG) delivered strong Q1 results with revenue up 14% and exceeding procedure growth expectations.
While facing challenges in manufacturing and supply chain, the company is focusing on R&D progress and inventory replenishment.
The outlook for 2023 looks promising with increased procedure growth forecasts and a focus on improving patient outcomes and market expansion.
Overall, Intuitive Surgical (ISRG) is well-positioned to capitalize on opportunities for growth and innovation in the robotic surgery market.

Intuitive Surgical excels in Q2 performance, eyes AI opportunities

Intuitive Surgical's Q2 2023 performance showcased strong revenue growth, procedure increases, and a focus on healthcare improvement.
The company's strengths include innovative ecosystem investments, commitment to patient outcomes, and advanced surgical technologies.
Challenges include market disruptions from new drugs, expense management, and adapting to changing healthcare landscapes.
Opportunities in AI, market expansion, and new procedures position Intuitive Surgical for continued growth and innovation.

Intuitive Surgical excels in Q3, eyes global expansion and margin growth

Intuitive Surgical's Q3 performance reflects strong growth and strategic focus on innovation and market expansion. Despite challenges in specific procedure categories and pricing dynamics, the company is well-positioned to capitalize on opportunities for growth and margin improvement.

Intuitive Surgical posts strong 2023 results, da Vinci 5 launch ahead

Intuitive Surgical's 2023 performance reflects strong revenue growth, operational excellence, and a strategic focus on innovation with the upcoming da Vinci 5 launch.
While facing challenges in operating margin pressure and supply chain issues, the company is well-positioned to capitalize on opportunities in soft tissue surgery, big data integration, and leased placements.
Investors should monitor how Intuitive Surgical navigates the launch of da Vinci 5, manages operational challenges, and leverages growth opportunities to sustain its market leadership.
Overall, Intuitive Surgical's Q4 earnings call highlights a resilient business model, customer-centric approach, and a commitment to advancing surgical technology for better patient outcomes.

Intuitive Surgical posts robust Q1 results amidst global market challenges

Intuitive Surgical delivered strong Q1 results with notable procedure and revenue growth, despite challenges in certain markets.
The company's focus on newer platforms, operational efficiency, and strategic outlook for 2024 positions it for continued success.
Addressing challenges and seizing opportunities in global markets and product innovation will be key for sustained growth and competitiveness.

Intuitive Surgical excels in Q2, eyes global expansion and innovation

Intuitive Surgical's Q2 performance reflects strength in procedure growth and system platform advancements.
The company's commitment to innovation and value creation positions them well for future success.
Challenges include sustaining margins and navigating market dynamics, while opportunities lie in expansion and innovation.
Overall, Intuitive Surgical's focus on growth, technology, and patient care sets a positive trajectory for the future.

Intuitive Surgical excels in Q3 with strong growth and innovation

Intuitive Surgical's Q3 2024 performance reflects a company in a strong position with notable achievements in procedures, financials, and technological advancements. While facing challenges in margin progression and international expansion, the company is well-positioned to leverage opportunities in innovation and customer insights.

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

In the closing of the recent trading day, Intuitive Surgical, Inc. (ISRG) stood at $490.01, denoting a +1.64% change from the preceding trading day.

Here's Why Intuitive Surgical, Inc. (ISRG) Gained But Lagged the Market Today

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Is It Worth Investing in Intuitive Surgical (ISRG) Based on Wall Street's Bullish Views?

Intuitive Surgical, Inc. (ISRG) concluded the recent trading session at $483.32, signifying a -1.64% move from its prior day's close.

Intuitive Surgical, Inc. (ISRG) Stock Falls Amid Market Uptick: What Investors Need to Know

Intuitive Surgical is making strides in the robotic-assisted surgery market with its existing and new launches. However, macro challenges are likely to continue to hurt its performance.

ISRG Stock Rallies 14% in 3 Months: Is It Still Worth Buying?

Salesforce

Enphase Energy

Investors are on edge as the Federal Reserve prepares to make its next interest rate decision. While some scramble for cover, seasoned investors seek opportunities in companies poised to weather the storm and thrive, regardless of the Fed's move.

Rate Cuts or Not, These 3 Stocks Are Poised to Outperform

Masimo

Veracyte

Chicago, IL – September 16, 2024 – Today, Zacks Equity Research discusses Intuitive Surgical ISRG, Masimo Corp. MASI and Veracyte, Inc. VCYT.

Zacks Industry Outlook Intuitive Surgical, Masimo and Veracyte

ISRG, MASI and VCYT from the Zacks Medical Instruments industry are worth buying based on genAI adoption, strategic developments and strong fundamentals. Yet, geopolitical complications and wage and supply issues mar the prospects.

3 Medical Instruments Industry Stocks to Buy on genAI and M&A Boost

DaVita

SharkNinja Inc

Stocks making new highs tend to make even higher highs, particularly when positive earnings estimate revisions hit the tape. And that's precisely what these three companies have seen.

3 Red Hot Stocks Flashing Buy Signals: DVA, ISRG, SN

Intuitive Surgical, Inc. (ISRG) concluded the recent trading session at $490.93, signifying a +1.38% move from its prior day's close.

Intuitive Surgical, Inc. (ISRG) Rises Higher Than Market: Key Facts

Netflix

First Trust NASDAQ-100 Technology Sector Index Fund

CNBC published an article in late August discussing some non-technology stocks investors were buying heading into the final months of 2024.

Buy These 4 Stocks For a Market Beating Portfolio

In the most recent trading session, Intuitive Surgical, Inc. (ISRG) closed at $476.69, indicating a -1.05% shift from the previous trading day.

Intuitive Surgical, Inc. (ISRG) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Intuitive Surgical, Inc. (NASDAQ:ISRG ) Wells Fargo 2024 Healthcare Conference September 5, 2024 9:30 AM ET Company Participants Brandon Lamm - Investor Relations Jamie Samath - Chief Financial Officer Conference Call Participants Larry Biegelsen - Medical Device Analyst, Wells Fargo Larry Biegelsen Good morning. Welcome back.

Intuitive Surgical, Inc. (ISRG) Wells Fargo 2024 Healthcare Conference (Transcript)

ISRG's shares gain on the back of strength in da Vinci surgical system.

Intuitive Surgical Gains 40.5% Year to Date: What's Driving the Stock?

Intuitive Surgical (NASDAQ: ISRG) has seen solid gains of over 80% from levels of around $270 in early January 2021 to nearly $500 now, vs. an increase of about 50% for the S&P 500 over this period.

Why Is Intuitive Surgical Stock Up 80%?

UnitedHealth Group

Even as some sectors face uncertainty, healthcare spending is on the upswing. Industry powerhouse UnitedHealth Group is rising above its short-term challenges.

2 Top Healthcare Growth Stocks to Buy Right Now

Broadcom

Pinterest

“It takes money to make money.” While that used to be true on Wall Street, it is no longer the case.

Only Have $1,000 to Invest? Buy These 3 Stocks Right Now

Recently, Zacks.com users have been paying close attention to Intuitive Surgical (ISRG). This makes it worthwhile to examine what the stock has in store.

Investors Heavily Search Intuitive Surgical, Inc. (ISRG): Here is What You Need to Know

AbbVie

3 Best Growth Stocks to Own for the Next 10 Years

Against expectations of a growth slowdown, Intuitive Surgical's results have been strong in 2024, supported by robust procedure volumes and a solid da Vinci 5 launch. Intuitive Surgical's margins picked up in Q2, despite the scaling of da Vinci 5 sales. Margins will come under pressure in coming quarters though as additional costs begin to hit. Intuitive Surgical has a large competitive advantage and a long growth runway, but its valuation will make it difficult for the company to generate strong returns.

Intuitive Surgical: Detached From Fundamentals

Ulta Beauty

Different companies have responded to the bull market in a variety of ways. Intuitive Surgical has seen shares soar as procedure volume and revenue increase steadily.

2 Top Growth Stocks You Can Still Buy in August

Intuitive Surgical, Inc. (ISRG) concluded the recent trading session at $486.55, signifying a -0.79% move from its prior day's close.

Intuitive Surgical, Inc. (ISRG) Stock Drops Despite Market Gains: Important Facts to Note

Form 13Fs allow investors to see which stocks Wall Street's prominent money managers have been buying and selling. More than a half-dozen billionaires dumped shares of artificial intelligence (AI) leader Nvidia for a third consecutive quarter.

Forget Nvidia: Billionaires Are (Still) Selling It and Buying Shares of These 2 Hypergrowth Stocks Hand Over Fist Instead

Intuitive Surgical (ISRG) continues to raise optimism among investors owing to its strength in robotics.

Reasons to Add Intuitive Surgical (ISRG) to Your Portfolio Now

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Is Intuitive Surgical (ISRG) a Buy as Wall Street Analysts Look Optimistic?

Brinker International

Advisorshares Restaurant ETF

FedEx

Host Hotels & Resorts

Real Estate Select Sector SPDR Fund

Health Care Select Sector SPDR Fund

SPDR S&P Transportation ETF

The annual inflation rate in the United States slowed for a fourth successive month in July 2024.

News for Intuitive Surgical Stock (ISRG)